pantoprazole has been researched along with imatinib mesylate in 5 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (40.00) | 29.6817 |
| 2010's | 2 (40.00) | 24.3611 |
| 2020's | 1 (20.00) | 2.80 |
| Authors | Studies |
|---|---|
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Breedveld, P; Cipriani, G; Pluim, D; Schellens, JH; Schinkel, AH; van Tellingen, O; Wielinga, P | 1 |
| Beijnen, JH; Buckle, T; Oostendorp, RL; Schellens, JH; van Tellingen, O | 1 |
| Belhassan, F; Gizurarson, S; Hada, N; Netzer, WJ; Wennogle, LP | 1 |
| Li, X; Meade, J; Ruiz-Soto, R; Shelton, MJ; Wang, J | 1 |
5 other study(ies) available for pantoprazole and imatinib mesylate
| Article | Year |
|---|---|
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
The effect of Bcrp1 (Abcg2) on the in vivo pharmacokinetics and brain penetration of imatinib mesylate (Gleevec): implications for the use of breast cancer resistance protein and P-glycoprotein inhibitors to enable the brain penetration of imatinib in pat
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Acridines; Animals; ATP Binding Cassette Transporter, Subfamily B, Member 1; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Benzamides; Benzimidazoles; Biological Transport; Brain; Dogs; Drug Synergism; Humans; Imatinib Mesylate; Male; Membranes; Methotrexate; Mice; Mice, Knockout; Neoplasm Proteins; Omeprazole; Pantoprazole; Piperazines; Pyrimidines; Spodoptera; Sulfoxides; Tetrahydroisoquinolines | 2005 |
The effect of P-gp (Mdr1a/1b), BCRP (Bcrp1) and P-gp/BCRP inhibitors on the in vivo absorption, distribution, metabolism and excretion of imatinib.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Absorption; Acridines; Animals; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Benzamides; Bile; Brain; Drug Combinations; Drug Resistance, Neoplasm; Feces; Female; Imatinib Mesylate; Kidney; Liver; Metabolic Clearance Rate; Mice; Mice, Knockout; Pantoprazole; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Tetrahydroisoquinolines | 2009 |
Nose-to-brain transport of imatinib mesylate: A pharmacokinetic evaluation.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Acridines; Administration, Intranasal; Animals; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B, Member 1; Biological Transport; Brain; Epinephrine; Female; Imatinib Mesylate; Injections, Intravenous; Male; Mice, Inbred BALB C; Nasal Mucosa; Pantoprazole; Protein Kinase Inhibitors; Tetrahydroisoquinolines | 2017 |
Effects of CYP3A Inhibition, CYP3A Induction, and Gastric Acid Reduction on the Pharmacokinetics of Ripretinib, a Switch Control KIT Tyrosine Kinase Inhibitor.
Topics: Adult; Cytochrome P-450 CYP3A Inducers; Cytochrome P-450 CYP3A Inhibitors; Drug Therapy, Combination; Gastric Acid; Humans; Imatinib Mesylate; Itraconazole; Naphthyridines; Pantoprazole; Protein Kinase Inhibitors; Proton Pump Inhibitors; Rifampin; Urea | 2022 |